{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:39:12Z","timestamp":1773970752885,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370577"],"award-info":[{"award-number":["82370577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070588"],"award-info":[{"award-number":["82070588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.scib.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:45:44Z","timestamp":1704714344000},"page":"850-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["From HFpEF to \u201cmetabolic (dysfunction)-associated HFpEF\u201d: Time to act"],"prefix":"10.1016","volume":"69","author":[{"given":"Xiao-Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2024.01.006_b0005","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/ejhf.1091","article-title":"Predictors and outcomes of heart failure with mid-range ejection fraction","volume":"20","author":"Bhambhani","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.scib.2024.01.006_b0010","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2024.01.006_b0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: The PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.scib.2024.01.006_b0020","doi-asserted-by":"crossref","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 2012;33:1750\u20131757.","DOI":"10.1093\/eurheartj\/ehr254"},{"key":"10.1016\/j.scib.2024.01.006_b0025","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2024.01.006_b0030","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2024.01.006_b0035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCULATIONAHA.119.045171","article-title":"Can HFpEF and HFrEF coexist?","volume":"141","author":"Schiattarella","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2024.01.006_b0040","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: Heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.scib.2024.01.006_b0045","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: From mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.scib.2024.01.006_b0050","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1161\/ATVBAHA.121.316664","article-title":"Matrix Gla protein levels are associated with arterial stiffness and incident heart failure with preserved ejection fraction","volume":"42","author":"Malhotra","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.scib.2024.01.006_b0055","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.1038\/s41598-020-69013-y","article-title":"Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction","volume":"10","author":"Miller","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.scib.2024.01.006_b0060","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41588-023-01518-4","article-title":"Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification","volume":"55","author":"Kavousi","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.scib.2024.01.006_b0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.122.063075","article-title":"Targeting epsins to inhibit fibroblast growth factor signaling while potentiating transforming growth factor-\u03b2 signaling constrains endothelial-to-mesenchymal transition in atherosclerosis","volume":"147","author":"Dong","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2024.01.006_b0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: Unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.scib.2024.01.006_b0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2024.01.006_b0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.scib.2024.01.006_b0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.scib.2024.01.006_b0090","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","article-title":"Clinical utility of the MAFLD definition","volume":"74","author":"Zheng","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.scib.2024.01.006_b0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","article-title":"Cardiometabolic HFpEF: NASH of the heart","volume":"147","author":"Capone","year":"2023","journal-title":"Circulation"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927324000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927324000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:59:12Z","timestamp":1761868752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927324000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2095927324000112"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2024.01.006","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From HFpEF to \u201cmetabolic (dysfunction)-associated HFpEF\u201d: Time to act","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.","name":"copyright","label":"Copyright"}]}}